barrett's%20esophagus
BARRETT'S ESOPHAGUS
Barrett's esophagus is defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology.
It is considered a premalignant metaplastic condition that usually involves the distal esophagus.
It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process.

Principles of Therapy

  • Patients with Barrett’s have greater esophageal acid exposure than other gastroesophageal reflux disease (GERD) patients
  • Goal of acid suppression in Barrett’s esophagus patients is to control the signs and symptoms of GERD and maintain healed mucosa
    • Treatment of Barrett’s esophagus aims to diminish the reflux of acid into the esophagus
  • There is no anti-reflux treatment that has been proven to decrease the risk of esophageal adenocarcinoma
  • Aggressive medical treatment with proton pump inhibitors (PPIs) and histamine2-receptor antagonist (H2RAs) to produce near-complete achlorhydria has been recommended
    • However, relief of symptoms does not correlate well with complete acid control

Pharmacotherapy

Proton Pump Inhibitors (PPIs)

  • Commonly used as 1st-line therapy especially in severe esophagitis
  • Given to patients with Barrett’s esophagus with or without GERD symptoms or signs of reflux esophagitis on endoscopy
  • If once-daily dosing of PPIs does not control symptoms, increasing the dose to twice daily is appropriate

Histamine2-Receptor Antagonists (H2RAs)

  • May be sufficient for patients with short-segment disease and only mild esophagitis

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
28 Aug 2017
Relamorelin appears to be effective in reducing core symptoms of gastroparesis, as well as improving overall composite symptom severity score and accelerated gastric emptying, in diabetic patients with moderate to severe gastroparesis, according to the results of a phase IIB trial.
Chistopher S Pokorny, 01 Dec 2013

Angela, a 28-year-old woman who is 14 weeks pregnant, presents to her GP with a 2-month history of intermittent rectal bleeding. Over this period, she has been passing bright blood on to her toilet paper, and at times into the toilet bowl. In addition, her stools are looser than in the past, and she reports occasional urgency. There has been no abdominal pain or weight loss. Her general health is good, and she is not taking any regular medications. There is no relevant family history.